Description Bacterium that causes respiratory tract infections and atypical pneumonia
Structure Chlamydia pneumoniae is an obligate intracellular Gram-negative bacterium belonging to the family Chlamydiaceae. Like other Chlamydia species, it possesses a unique biphasic developmental cycle consisting of an infectious elementary body (EB) and a metabolically active reticulate body (RB). Elementary bodies are responsible for transmission and host cell invasion, whereas reticulate bodies replicate within membrane-bound intracellular inclusions. Chlamydia pneumoniae is a strictly human pathogen and is transmitted primarily through respiratory droplets. The organism infects epithelial cells and macrophages within the respiratory tract and is a common cause of community-acquired respiratory infections worldwide. Chronic or persistent infection has also been investigated for possible associations with atherosclerosis, asthma, and other chronic inflammatory conditions, although these relationships remain incompletely understood.
Diagnosis The diagnosis of Chlamydia pneumoniae infection is performed through molecular, serological, and microbiological methods. Polymerase chain reaction (PCR) assays are considered the most sensitive and specific diagnostic tools and allow direct detection of bacterial DNA in respiratory specimens. Serological testing using ELISA, microimmunofluorescence (MIF), or complement fixation assays may be used to detect Chlamydia pneumoniae-specific antibodies and assess recent or past infection. Culture is technically demanding because the organism is an obligate intracellular pathogen and is rarely performed outside specialized laboratories. Diagnosis often relies on a combination of clinical presentation, imaging findings, and laboratory testing due to the nonspecific nature of symptoms.
Symptoms Chlamydia pneumoniae infection typically develops following an incubation period of approximately three to four weeks. The disease commonly presents as a mild upper respiratory tract infection characterized by sore throat, hoarseness, runny nose, headache, fatigue, and low-grade fever. Infection may progress to bronchitis or atypical pneumonia, resulting in persistent dry cough, chest discomfort, shortness of breath, and malaise. Symptoms often develop gradually and may persist for several weeks. While most infections are self-limiting, severe disease can occur in elderly individuals, immunocompromised patients, and those with underlying cardiopulmonary disorders. Reinfections are common throughout life due to incomplete protective immunity.
Data
FAQ & Publications
Frequently Asked Questions
For which assay applications is the Chlamydia pneumoniae IgA Control Serum BC1371A intended?
The Chlamydia pneumoniae IgA Control Serum BC1371A is designed for use in ELISA applications, specifically as a control serum for indirect and quantitative assays.
How should the Chlamydia pneumoniae IgA Control Serum BC1371A be stored to maintain its stability?
This control serum should be stored at refrigerated temperatures between 2-8°C to preserve its integrity and ensure reliable assay performance.
Is the Chlamydia pneumoniae IgA Control Serum BC1371A compatible with SERION ELISA kits?
Yes, the serum is ready-to-use and pre-diluted specifically for compatibility with SERION ELISA classic and SERION ELISA antigen assays.
Publications
pmid
title
authors
citation
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.
Reviews
There are no reviews yet.